The patient has a diagnosis of chronic or episodic migraine.
Women suffering from migraine with or without aura according to International Headache Society (IHS) Classification (ICHD-3 code A1.1.2 or A1.2.0.2) for at least one year.
The patient has been maintaining a daily headache diary as part of her routine disease management per her treating physician and has 3 months headache diary data prior to baseline/ treatment initiation. Notes: The patient's headache diary captures information on each headache day, headache duration, headache severity, medication intake, each day of menstrual bleeding, pain intensity of symptoms associated with the menstrual bleeding and symptoms of endometriosis (if present): dysmenorrhoea, dyschezia, dyspareunia, dysuria.
The patient understands and is willing to keep records in their headache diary for the course of the study.
Initiation of anti-CGRP mAb (fremanezumab) treatment according to the Summary of Product Characteristics (SmPC) during clinical routine as a treatment of their physician (no study-specific intervention). This means that patients have to fulfil criteria for treatment with anti-CGRP mAbs in Switzerland, i.e. they have at least 8 days of migraine per month in the last three months.
The patient has signed the informed consent.
You may not be if
Patients with pure menstrual migraine.
The patient is treated with another anti-CGRP mAb.
The patient is not treated with fremanezumab according to the SmPC.
The patient is being treated with another anti-CGRP-based preventive migraine medication within 6 months of enrolment.
The patient is participating in an interventional clinical trial in EM or CM.
